Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,200.00
Bid: 12,884.00
Ask: 9,725.00
Change: 44.00 (0.36%)
Spread: -3,159.00 (-24.519%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Lower call; JD Sports suffers interim profit fall

Thu, 22nd Sep 2022 07:46

(Alliance News) - Stocks in London are set to open lower on Thursday, ahead of a major interest rate decision by the Bank of England and a day after the US Federal Reserve settled for another three-quarter-point rate hike.

The Federal Reserve "will keep at it" until inflation is well and truly tackled, Chair Jerome Powell said on Wednesday after a third successive 75 basis point rate hike by the central bank.

A third 75 basis point hike on-the-trot took the target range for the federal funds rate to 3.00% to 3.25%. The three-quarter point hike was largely what the market expected, though there had been some that believed the Fed would turn to a 1% lift.

On Thursday, the latest Bank of England will unveil its own interest rate decision at 1200 BST.

At the previous meeting, the BoE increased bank rate by half a percentage point to 1.75% from 1.25%. It was the largest rate rise since 1995.

In the US on Wednesday, Wall Street ended firmly in the red and the dollar was stronger following the US Fed decision.

In early UK corporate news on Thursday, sportswear retailer JD Sports announced a rise in interim revenue but a drop in profit, though it said the results were ahead of expectations.

Here is what you need to know ahead of the London market open:

----------

MARKETS

----------

FTSE 100: called down 0.9% at 7,173.60

----------

Hang Seng: down 1.9% at 18,098.41

Nikkei 225: closed down 0.6% at 27,153.83

Sydney market closed for holiday.

----------

DJIA: closed down 522.45 points, 1.7%, at 30,183.78

S&P 500: closed down 1.7% at 3,789.93

Nasdaq Composite: closed down 1.8% at 11,220.19

----------

EUR: down at USD0.9819 (USD0.9879)

GBP: down at USD1.1230 (USD1.1336)

USD: up at JPY145.25 (JPY144.13)

Gold: down at USD1,659.25 per ounce (USD1,667.36)

Oil (Brent): up at USD90.30 a barrel (USD89.80)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

Australia National Holiday holiday. Financial markets closed.

16:00 CEST EU flash consumer confidence

12:00 BST UK BoE interest rate decision

08:30 EDT US unemployment claims

08:30 EDT US weekly export sales

10:00 EDT US leading indicators

11:00 EDT US Fed Kansas City survey

16:30 EDT US federal discount window borrowings

16:30 EDT US foreign central bank holdings

----------

EU foreign policy chief Josep Borrell has promised new sanctions targeting Russia following President Vladimir Putin's latest escalation in his war against Ukraine. "We decided to bring forward as soon as possible additional restrictive measures against Russia in coordination with partners," Borrell said late on Wednesday following a meeting of EU foreign ministers on the sidelines of the UN General Assembly in New York. The meeting was convened by Borrell after Putin ordered the partial mobilization of reservists in order to bolster his military's flagging efforts in Ukraine.

----------

Manufacturers in the UK have slashed their growth forecasts for next year amid "gathering storm clouds" for industry. Make UK said a survey of firms suggested growth in the sector of just 0.6% in 2023, down from 1.7% as recently as June. The manufacturers' organisation has cut its forecast for economic growth from 3.6% this year to 0.3% in 2023. Make UK called on the government to bring forward a "shock and awe" package of policy measures in its mini-budget on Friday in line with those seen during the worst points of the pandemic to help protect viable companies and avert significant job losses.

----------

BROKER RATING CHANGES

----------

Berenberg cuts Aveva Group to 'hold' from 'buy'

----------

JPMorgan reinitiates FirstGroup with 'overweight'

----------

RBC starts Ceres Power with 'sector perform'

----------

COMPANIES - FTSE 100

----------

Sportswear retailer JD Sports announced a rise in interim revenue but a drop in profit, which it said was due to the previous year experiencing a one-off benefit in the US from government stimulus. In the six months to July 30, revenue rose to GBP4.42 billion from GBP3.89 billion a year previous. Cost of sales ticked up to GBP2.28 billion from GBP2.00 billion. Pretax profit dropped to GBP298.3 million from GBP364.6 million. Chair Andrew Higginson says the results were at the "top end" of the company's expectations. JD Sports reinstated an interim dividend of 0.13 pence per share. It added that it expects its pretax profit for the year as a whole to be in line with the record performance for the year that ended this past January 29.

----------

Safety equipment maker Halma said its progress in the first half of its financial year to date has been in line with expectations, despite a challenging operational environment. It noted strong demand for products and services, with order intake "strongly" ahead of both revenue in the year to date and order intake for the same period last year. Halma left its revenue growth guidance for the full-year unchanged at "good single digit percentage organic constant currency revenue growth."

----------

Pharmaceutical firm AstraZeneca, along with American pharmaceutical firm Merck & Co, announced that Lynparza has been approved in China for the treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency-positive status. The approval was based on a Paola-1 phase III trial which showed Lynparza plus bevacizumab demonstrated a substantial progression-free survival improvement versus bevacizumab alone for patients with HRD-positive advanced ovarian cancer.

----------

Telecommunications firm BT said that its workers, along with those at Openreach, are to stage fresh strikes in a long-running dispute over pay. The Communication Workers Union said its members will walk out on October 6, 10, 20 and 24. The action will include the tens of thousands of Openreach engineers and BT call centre workers who have walked out in previous months. The dispute centres on workers opposing the imposition by company management of an "incredibly low" flat-rate pay rise of GBP1,500 which the union said was a real-terms pay cut because of the soaring rate of inflation.

----------

COMPANIES - FTSE 250

----------

Gambling software firm Playtech reported a fall in pretax profit but a rise in revenue in the six months ended June 30. Revenue jumped to EUR792.3 million from EUR457.4 million, while pretax profit fell to EUR103.7 million from EUR278.1 million. The fall in profit was balmed on "EUR299.9 million of unrealised fair value gains on derivative financial assets recognised in the prior period." Chief Executive Mor Weizer said the performance was ahead of expectations and powered by Playtech's B2B business in the Americas and Europe. Weizer added that this "excellent" performance has continued into the second half of the year.

----------

Personal healthcare and consumer goods maker PZ Cussons posted a "resilient" performance in the year ended May 31, with dips in both revenue and profit amid a "challenging" market backdrop. In the year, revenue slipped by 1.7% to GBP592.8 million from GBP603.3 million. Pretax profit declined 8.7% to GBP65.3 million from GBP71.5 million. Cost of sales grew 11% year-on-year. PZ Cussons blamed the fall in profit on the reduction in revenue and a brand impairment. It increased its final dividend to 6.40 pence from 6.09 pence, however. The company also noted a "good" start to financial 2023.

----------

OTHER COMPANIES

----------

Veterinary service provider CVS Group posted a rise in annual profit and revenue as the company benefited from favourable and "resilient" market dynamics in the year. In the year ended June 30, revenue rose 8.6% to GBP554.2 million from GBP510.1 million, while pretax profit climbed 8.8% to GBP36.0 million from GBP33.1 million. CVS also increased its final dividend to 7.0 pence per share from 6.5p the prior year. In the first 10 weeks of its new financial year, the firm reported strong sales and like-for-like growth against the previous year. CVS added that trading was in line with market expectations.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
Today 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.